666 related articles for article (PubMed ID: 15652238)
1. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of PDE3, PDE4 and PDE7 potentiates glucocorticoid-induced apoptosis and overcomes glucocorticoid resistance in CEM T leukemic cells.
Dong H; Zitt C; Auriga C; Hatzelmann A; Epstein PM
Biochem Pharmacol; 2010 Feb; 79(3):321-9. PubMed ID: 19737543
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.
Meyers JA; Taverna J; Chaves J; Makkinje A; Lerner A
Clin Cancer Res; 2007 Aug; 13(16):4920-7. PubMed ID: 17699872
[TBL] [Abstract][Full Text] [Related]
5. Activation and induction of cyclic AMP phosphodiesterase (PDE4) in rat pulmonary microvascular endothelial cells.
Zhu B; Kelly J; Vemavarapu L; Thompson WJ; Strada SJ
Biochem Pharmacol; 2004 Aug; 68(3):479-91. PubMed ID: 15242814
[TBL] [Abstract][Full Text] [Related]
6. PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A.
Moon EY; Lerner A
Blood; 2003 May; 101(10):4122-30. PubMed ID: 12531792
[TBL] [Abstract][Full Text] [Related]
7. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Seldon PM; Barnes PJ; Meja K; Giembycz MA
Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
[TBL] [Abstract][Full Text] [Related]
8. Preclinical assessment of curcumin as a potential therapy for B-CLL.
Everett PC; Meyers JA; Makkinje A; Rabbi M; Lerner A
Am J Hematol; 2007 Jan; 82(1):23-30. PubMed ID: 16947318
[TBL] [Abstract][Full Text] [Related]
9. Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis.
Tiwari S; Felekkis K; Moon EY; Flies A; Sherr DH; Lerner A
Blood; 2004 Apr; 103(7):2661-7. PubMed ID: 14615375
[TBL] [Abstract][Full Text] [Related]
10. Effect of adrenaline and glucocorticoids on monocyte cAMP-specific phosphodiesterase (PDE4) in a monocytic cell line.
Delgado M; Fernández-Alfonso MS; Fuentes A
Arch Dermatol Res; 2002 Jul; 294(4):190-7. PubMed ID: 12111350
[TBL] [Abstract][Full Text] [Related]
11. Effect of phosphodiesterase antagonists on glucocorticoid mediated growth inhibition in murine skin cell lines.
Kowalczyk P; Kinjo T; Kowalczyk M; Walaszek Z; Hanausek M; Slaga TJ
Eur J Pharmacol; 2009 May; 610(1-3):29-36. PubMed ID: 19306867
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
[TBL] [Abstract][Full Text] [Related]
13. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia.
Kim DH; Lerner A
Blood; 1998 Oct; 92(7):2484-94. PubMed ID: 9746789
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.
Tan Y; Watkins AA; Freeman BB; Meyers JA; Rifkin IR; Lerner A
J Immunol; 2015 Jan; 194(1):101-12. PubMed ID: 25416804
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Biochem Pharmacol; 2005 Jan; 69(2):267-75. PubMed ID: 15627479
[TBL] [Abstract][Full Text] [Related]
17. Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition.
Oger S; Behr-Roussel D; Gorny D; Denys P; Lebret T; Alexandre L; Giuliano F
Eur Urol; 2007 Mar; 51(3):772-80; discussion 780-1. PubMed ID: 17097801
[TBL] [Abstract][Full Text] [Related]
18. A role for cyclic nucleotide phosphodiesterase 4 in regulation of the growth of human malignant melanoma cells.
Narita M; Murata T; Shimizu K; Nakagawa T; Sugiyama T; Inui M; Hiramoto K; Tagawa T
Oncol Rep; 2007 May; 17(5):1133-9. PubMed ID: 17390056
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells.
Ogawa R; Streiff MB; Bugayenko A; Kato GJ
Blood; 2002 May; 99(9):3390-7. PubMed ID: 11964308
[TBL] [Abstract][Full Text] [Related]
20. Profiling of functional phosphodiesterase in mesangial cells using a CRE-SEAP-based reporting system.
Zhu Y; Yao J; Meng Y; Kasai A; Hiramatsu N; Hayakawa K; Miida T; Takeda M; Okada M; Kitamura M
Br J Pharmacol; 2006 Jul; 148(6):833-44. PubMed ID: 16751794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
